DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award (PCTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of amyotrophic lateral sclerosis (ALS). Projects may range fro
| Agency | Dept. of the Army -- USAMRAA |
|---|---|
| Status | Posted |
| Opportunity number | HT942526ALSRPPCTA |
| Posted date | 05/04/2026 |
| Application deadline | Sep 30, 2026 12:00:00 AM EDT |
| Award ceiling | none |
| Award floor | none |
| Estimated total funding | 5,600,000 |
| Expected number of awards | 2 |
| Assistance Listing (CFDA) | 12.420 |
| Description | Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award (PCTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of amyotrophic lateral sclerosis (ALS). Projects may range from phase 1 to small-scale phase 2 trials. Applications must address one of the following focus areas: · Biomarker-Driven Interventions: Disease-modifying interventions, with mechanism-specific biomarkers to predict which clinical trial participants are likely to respond, demonstrate target engagement, and effects on the intended biological pathway. · Clinical Care: Improving aspects of clinical care and symptom management for ALS. Distinctive Features: Funding from this award |
| Agency contact | help@eBRAP.org |
| Official listing | https://www.grants.gov/search-results-detail/362195 |